

Appl. No. 10/790,378  
Amdt. dated May 23, 2005  
Reply to Office Action Mailed March 8, 2005

**REMARKS**

The above-referenced application has been reviewed in light of the Office Action mailed March 8, 2005. It is respectfully submitted that the claims pending in the application, namely claims 1-17, do not introduce new subject matter, are fully supported by the specification, and are patentable over the prior art. Prompt and favorable consideration of these claims is earnestly sought.

The Office Action rejected claims 1-17 under the judicially created doctrine of obviousness-type double patenting over claims 1-10, 13-17, 19, and 20 of U.S. Patent No. 5,968,066 to Fogarty et al. In response thereto, Applicants hereby submit a terminal disclaimer in accordance with 37 C.F.R. § 1.321(c) and the fee required under 37 C.F.R. § 1.20(d). It is respectfully submitted that the Office Action's obviousness-type double patenting rejection of claims 1-17 has been overcome.

Please charge the fees required under 37 C.F.R. § 1.20 (d) to Deposit Account **21-0550**.


**TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.**

Appl. No. 10/790,378  
Amdt. dated May 23, 2005  
Reply to Office Action Mailed March 8, 2005

In view of the foregoing amendments and remarks, it is respectfully submitted that all claims pending in the application, namely claims 1-17, are in condition for allowance. Should the Examiner desire a telephonic interview to resolve any outstanding matters, he is sincerely invited to contact the undersigned at (631) 501-5713.

Respectfully submitted,

Carter, DeLuca, Farrell & Schmidt, LLP  
445 Broad Hollow Road - Suite 225  
Melville, New York 11747  
Tel.: (631) 501-5713  
Fax: (631) 501-3526

  
Dana A. Brussel  
Reg. No. 45,717  
Attorney for Applicants

**Send correspondence to:**  
Chief Patent Counsel  
Tyco Healthcare Group  
150 Glover Avenue  
Norwalk, CT 06856